What do systematic reviews say?

Self‐management interventions vs usual care

• Self‐management interventions including action plans for exacerbations versus usual care in patients with chronic… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1582 participants
  High

Self‐management interventions vs usual care

• Self‐management interventions including action plans for exacerbations versus usual care in patients with chronic… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 217 participants
  Low

Self‐management interventions vs usual care

Self‐management interventions including action plans for exacerbations showed no clear difference in courses of oral steroids compared with usual care (low certainty).

• Self‐management interventions including action plans for exacerbations versus usual care in patients with chronic… 2017 · Cochrane Headline outcomes only
  OR 4.38 [0.55, 34.91]
  4 studies · 963 participants
  Low

Breathing exercises as part of a package of interventions vs control

• Breathing exercises for children with asthma 2016 · Cochrane Headline outcomes only
  no estimate extracted
  28 participants
  Low

Breathing exercises as part of a package of interventions vs control

• Breathing exercises for children with asthma 2016 · Cochrane Headline outcomes only
  no estimate extracted
  78 participants
  Low

Breathing exercises as part of a package of interventions vs control

The review found no eligible studies for this question.

• Breathing exercises for children with asthma 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  17 studies · 22819 participants
  GRADE not reported

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  Low

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 679 participants
  Low

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 7569 participants
  Moderate

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1759 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 5681 participants
  GRADE not reported

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1005 participants
  High

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 774 participants
  Moderate

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2863 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 3003 participants
  Moderate

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 4276 participants
  GRADE not reported

Intervention not reported

• Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  Very low